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Abstract: The 3Ks (kava, kratom and khat) are herbals that can potentially induce liver injuries. On the
one hand, growing controversial data have been reported about the hepatotoxicity of kratom, while,
on the other hand, even though kava and khat hepatotoxicity has been investigated, the hepatotoxic
effects are still not clear. Chronic recreational use of kratom has been associated with rare instances of
acute liver injury. Several studies and case reports have suggested that khat is hepatotoxic, leading to
deranged liver enzymes and also histopathological evidence of acute hepatocellular degeneration.
Numerous reports of severe hepatotoxicity potentially induced by kava have also been highlighted,
both in the USA and Europe. The aim of this review is to focus on the different patterns and the
mechanisms of hepatotoxicity induced by “the 3Ks”, while trying to clarify the numerous aspects
that still need to be addressed.
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1. Introduction
Liver damage caused by herbal medicines, also called herb induced liver injury (HILI), is a rare
event that occurs in a small number of susceptible individuals [1–3]. Its characteristics are similar
to those of drug induced liver injury (DILI). Commonly in HILI and DILI cases, injury is related to
idiosyncratic reaction that occurs at recommended doses [4]. The diagnosis of HILI generates both
regulatory and clinical challenges. The assessment of causality according to Teschke et al. [2] should be
performed using the Council for International Organizations of Medical Sciences Scale (CIOMS), also
known as RUCAM (Roussel Uclaf Causality Assessment Method) [4], which is specific for the liver and
validated for hepatotoxicity. Moreover, even though herbal supplements are under regulation in many
countries, standard levels could dramatically differ, including the possibility of herb misidentification,
the presence of impurities and/or adulterants. Naranjo scale, the ad hoc approach and the World Health
Organization (WHO) method are not equal to the CIOMS scale in the evaluation of HILI causality.
However, if HILI is caused by herb intake, caution is mandatory and the compound must be avoided,
even when lacking causality assessment. Moreover, in order to achieve a diagnosis, it is necessary
to exclude several intra- and extra-hepatic causes. The most suitable criterion for HILI causality
assessment has been defined by some authors [5] to be a positive re-exposure reaction, if evaluated by
established test criteria.
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1.1. Kava: General Concepts
Kava is a traditional Pacific beverage made from the roots and stems of Piper methysticum Forst.
f. (“awa” meaning bitter in Hawaiian) plant, which belongs to the pepper family [6–8] (Figure 1). In
2002, the Vanuatu government approved the Kava Act [9], in which kava is identified in different
cultivars and categorized: noble cultivars (long history of safe use for traditional purposes), medicinal
(ancient and confirmed history of useful properties amongst traditional herbalists for therapeutic
properties), two days cultivars (able to intoxicate for two days and banned from export) and wichmannii
cultivars (Piper wichmannii, ancestor of P. methysticum, wild variety banned from export). One of the
favored noble cultivars is Borogu, which contains high quantities of kavain and dihydrokavain, and
is known for its quick effects [10]. The drinking of kava was sacred and its use was limited to
defined social classes such as priests and chiefs. The traditional drink is known to decrease anxiety
and fatigue, it produces a sociable attitude, relieves pain and induces sleep [11]. It was consumed
for its intoxicating properties in countries where alcohol fermentation only arrived at a later date.
This aqueous compound has been drunk for centuries in the southern Pacific, without any apparent
consequences, apart from kava dermopathy and if taken heavily it is associated with a raise of liver
enzymes, primarily γ-glutamyl-transpeptidase (γ-GT) even causing sudden cardiac death [12–18].
However, in Western countries, kava extracts (obtained by acetonic or ethanolic extraction) have been
used mainly for the treatment of anxiety [19] disorders and restlessness and have been linked with
hepatotoxicity, especially in females [20], with a mean average of 111 days from the first exposure until
the onset of liver impairment. Other authors suggest that kava hepatotoxicity can also be observed
after the intake of traditional aqueous kava preparation and therefore it should not be linked to
acetonic or ethanolic extraction, suggesting that the toxicity is due to the kava plant itself or to the
low quality of kava cultivar used and, more generally, to a lack of standardization in the production
of kava supplements or contamination [21–24]. As suggested by Lebot [25], major criteria for kava
quality are: chemotype, total kavalactone content, preparation and dilution method, part of the plant
used, and dry or fresh material use. According to Sorrentino et al. [26], kava products are to be
considered safe at the dosage of 100 mg/kg/day (even though this dosage corresponds to 10 times the
recommended daily dose) and, according to pre-clinical, clinical and toxicological studies, do not cause
toxicity [27]. The first cases of kava related hepatotoxicity were described by Strahl et al. [28] in 1998;
since then, more than 100 cases of severe liver injury following kava exposure have been suspected
worldwide. Kava products have been withdrawn from Europe, USA and Australia; moreover, Food
and Drug Administration (FDA) and Center for Disease Control (CDC) warnings and European
regulatory agency warnings have been diffused since 2002 [29,30]. In Italy, kava products were also
withdrawn from the market in 2002 [31]. However, possible damage mechanisms have not yet been
fully established, probably because of the numerous variables involved in kava products and as the
kava plant itself contains more than 40 constituents.
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1.2. Kratom: General Concepts
Kratom is a natural psychoactive preparation obtained from a plant known as Mitragyna speciosa
Korth, belonging to Rubiaceae or coffee family [32]. The tree of this genus has a widespread distribution,
both in the tropical and subtropical regions of Southeast Asia and in several areas of Africa. It is also
known as “biak-biak” or Ketum in Malaysia; Kratom, Kakuam, Kraton, Ithang or Thom in Thailand [33–36];
and Mambog in the Philippines [37]. The tree has wide, shiny, oval-shaped bright green-colored leaves
that can grow up to 18 cm in length and 10 cm in width. The flowers of the plant are yellow and have
a spherical shape with a cluster organization [37,38] (Figure 2).
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considered a legitimate remedy for any medical purpose [32,37,42]. Although kratom seems to be
safe when administered at 1–10 mg/kg doses (which represents a sub-chronic dose), after prolonged
exposure to a 100 mg/kg dose, as demonstrated in the experiments on Sprague-Dawley rats conducted
by Sabetghadam et al. [53], it causes biochemical and hematological changes with histopathological
alterations in several tissues (liver, kidney and brain). In the same paper, the authors reported
that kratom users consume about 67.5–75 mg of kratom per day and that no adverse effects were
shown while only after prolonged exposure to a higher dose of kratom, clinical signs of toxicity were
highlighted [41]. Only a few papers [54] report liver damages or hepatotoxic sequelae related to kratom
use, and also in these cases, the authors highlighted the difficulties of a correlation between kratom
consumption and hepatic injuries, which was more likely to be associated with the extraction process
of the alkaloids or to the presence of contaminants in the herbal products [52]. Moreover, causality
has not yet been accurately established for kratom, as CIOMS scale (RUCAM) has not been applied to
suspected cases. Further information is available in the drug user web fora [55]; although these are not
official sources, they could represent an incentive for researchers to enhance their knowledge of its
metabolism and its adverse effects in humans.
1.3. Khat: General Concepts
Catha edulis (khat) is a plant (Figure 3) with psychoactive effects, the most widely used in the
world. Grown in the east of Africa, in the Horn of Africa and southwest of the Arabian Peninsula,
the foliage and branches are used daily by more than 20 million people [56,57]. Historical evidence
highlights that khat has been in use since the 13th century in Ethiopia and in the east of the Arabian
region, before the cultivation of coffee. In the last thirty years it has become available and its use
has extended in the world, including North America and Europe. The main consumers in the West
are groups of immigrants from eastern Africa and the Middle East [56], especially immigrants from
Somalia, Ethiopia and Yemen [58]. According to the World Health Organization, khat is a drug of
abuse, due to the health problems it can cause. Although it is still legal in many countries, it is
forbidden in almost all Western countries such as Germany, France, Netherlands, United States and
Canada, while it is allowed in Somalia, Djibouti, Ethiopia, Yemen and Israel [56]. Catha edulis contains
a number of substances, among which the most important, cathinone and cathine, have a similar
effect to amphetamine. When chewing khat, cathinone is released producing a feeling of euphoria.
The production of cathine and norephedrine has been detected after cathinone is metabolized, and
its structure is related to amphetamine and adrenaline (epinephrine) [58,59]. Cathinone also reduces
appetite through an unknown mechanism. Murray et al. [60] observed that the level of cathinone is
related to a sense of satiety, but it does not affect the level of the two hormones which regulate feelings
of hunger and satiety, ghrelin and Peptide YY. Girma et al. have conducted a study on 385 people,
fat mass index (FMI) and body mass index (BMI) resulted lower in chewers than in non-chewers
(186 people) [61]. Khat also causes effects including, increased blood pressure associated with a rise in
the occurrence of vasospasms, acute myocardial infarction, unfavorable cardiovascular effects and
it can also determine problems related to the gastrointestinal tract: esophagitis, gastritis, a delay in
intestinal absorption and the development of lesions in the white keratotic oral site of chewing [56,62].
In the Pateria et al. [63] review, many cases of acute liver failure (ALF) have been described. In some
studies [64–66], many cases of autoimmune hepatitis among consumers of Catha edulis have also
been found. However, causality assessment through the use of RUCAM (CIOMS scale) has not been
systematically applied to the suggested cases. There are only a few articles that show the interaction of
khat with diseases and respective therapies in Africa. In southwest Ethiopia, many people with HIV are
also khat chewers. Soboca et al. [67], have found in these patients, a lower response to medicines and to
antiretroviral therapy (ART). Ketema et al. [68] have studied anti-plasmodial activities on Plasmodium
berghei ANKA (PbA), in the malaria infection on Swiss albino mice, orally treated with crude khat
(Catha edulis). Khat proved to be a poor anti-plasmodial, suppressing only 10% of the parasites without
lessening the main symptoms of the disease. Another study of Ketema et al. [69], aimed to evaluate the
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chewing of khat, the onset of severe malaria syndromes, and the immune response during the disease
in areas where malaria and this drug, coexist. The IgM and IgG antibody titers and the incidence of
jaundice and kidney failure were higher among the consumers, compared to non chewers.
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kavain, and 7,8-dihydrokavain [12], are shown in Figure 4. They represent 96% of kavalactones found
in kava roots [11]. Moreover, at least three alkaloids have been characterized in the aerial part of
the plant: awaine, pipermethystine (PM) and 3α,4α-epoxy-5β-pipermethystine (shown in Figure 5).
Only one cultivar out of the 11 tested (P. methysticum cv. Isa) contained the latter compound, and
this kava plant variety is seldom used to prepare the ceremonial drink because it causes protracted
nausea [74]. Several differences have been observed in the amount of constituents and distribution
in the different varieties of the Piper methysticum plant. The chemical compositions “Chemotype”
can be codified by listing in a diminishing order of proportion the major kavalactones found in the
extract, chemotype is genetically determined and depends mainly on the cultivar, and the quality is
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predominately due to the kavalactone concentration and chemotype [75]. Over 200 different strains of
kava have been recognized by chemo-typing, but the chemical signature can vary among the plant
portions (rhizomes, roots, basal stems) [76]. This great variability, along with the lack of standard
protocols for the preparation of kava extracts, leads to inconsistent evidence of toxicity. The plant also
contains minor constituents in the amount of <1% of the dry weight, called flavokawains (FK) A, B,
and C (chalcones are shown in Figure 6).
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2.1.2. Kratom
Since the 1960s, more than 25 alkaloids [77] have been isolated and characterized from
Mitragyna speciosa [32]: the alkaloid content is approximately from 0.5% to 1.5% [37] and it varies
from plant to plant [52] depending on the age of the plant tissues, the seasonality and the geographical
location. Mitragynine is the most abundant active compound, representing approximately 66.2% [78]
of the crude base total alkaloid content [52], that also consists of other minor indole compounds
structurally related to yohimbine and Uncaria alkaloids [32,37,42,79]. Mitragynine was first isolated
in 1907 by D. Hooper [80] and its structure was fully determined in 1965 by X-ray crystallography
by Zacharias [81]. It was initially considered to be the prime cause of the antinociceptive kratom
effects, since it has opioid-like effects 13-fold stronger than morphine, even though its chemical
structure is dissimilar to opiates. Several studies [79,82,83] have demonstrated that another compound,
7-hydroxymitragynine, which represents only a small percentage of the total alkaloid content of the
plant extract, presents analgesic effects on the central nervous system 40 times more potent than those
of mitragynine [37,78,79,84], probably due to its lipophilicity, which facilitates the crossing of the
blood–brain barrier [85]. The second most abundant alkaloid is paynantheine (about 10%), followed
by speciociliatine and speciogynine, isolated in percentages lower than 9%. 7-HMG represents only
approximately 2% of the total alkaloid content and other compounds (mitraphylline, rhynchophylline,
mitralactonal, raubasine and mitragynaline) [37] were observed in a percentage lower than 1%. The
most representative alkaloid agents found in kratom extract are reported in Figure 7.
Another alkaloid described and determined with spectroscopic analysis and chemical conversion
by Kitajima et al. in the fruits of the M. speciosa, is 7-hydroxyspeciociliatine [86]. For the total alkaloid
profile of M. speciosa Korth., see Hassan et al. [32]. The stimulating and analgesic/depressive effects,
caused by kratom consumption are mainly due to the presence of these numerous alkaloids: the
modulation of the above-mentioned effects is closely related not only to the dosage of consumption
but also to the strain of the leaves, since the alkaloid content varies also in relationship to the veining
varieties. In nature, there are three different leave strains: the red variety, originating from Bali, is
very efficient in pain relief, while the white one and green ones, originating from Malaysia, cause the
onset of strong stimulant effects. Other varieties of kratom are sold on the internet like Bali kratom,
Malaysian kratom, red, green or white vein Thai kratom, Maeng Da kratom, white-veined Borneo
kratom, New Guinea kratom, Java kratom, Sumatra red, the Rifat strain, the bumblebee strain, and
red and green Riau [52]. Furthermore, for each of these types, there are several grades of potency: the
“organic commercial grade” (the least potent), the “premium” or the “instand instant”, the “super”
and the “super enhanced” [87]. Little is known about the real potency of these preparations, except for
the experiences reported by the users in the web fora.
Int. J. Mol. Sci. 2016, 17, 580 8 of 30
Int. J. Mol. Sci. 2016, 17, 580 8 of 29 
 
 
Figure 7. Chemical structures of the most abundant indole alkaloids in M. speciosa. 
The ability of mitragynine to cause analgesic effects is linked to its interaction with supraspinal 
μ- and δ-receptors [32,37,42,84], while the onset of stimulant activity is due to the block of the 
stimulation of serotonergic 5-HT2A receptors and to the postsynaptic stimulation of the α-2 adrenergic 
receptors [84,88]. The antinociceptive mechanism of the 7-hydroxymitragynine is, instead, linked to 
its capacity of interaction with the μ-receptors, as shown by studies carried out on the tail-flick tests 
on mice, and partially by the affinity with κ-opioid receptors [89]. Kong et al. [90] evaluated the effect 
of the M. speciosa extract (MSE) on human recombinant cytochrome P450 enzymes: he observed that 
MSE shows a high inhibitory effect on CYP3A4 and CYP2D6, whereas a moderate inhibition was 
found for CYP1A2 and a weak inhibition for CYP2C19. These results suggest that the use of kratom 
could cause dangerous consequences if consumed concomitantly with other drugs that are substrates 
of the same enzymes. Many adverse effects are reported in the literature by several authors, including 
fatal cases caused by co-consumption with other substances, like carisoprodol [88], modafinil [91], 
propylhexedrine [92], Datura stramonium [93], fentanyl [88], diphenhydramine, temazepam [94], 
caffeine, morphine and O-desmethyltramadol [37,49,88]. 
However, there are few studies in the literature proving the toxicity of kratom in humans. 
Seizure episodes and withdrawal syndromes reported are mostly related to chronic consumption of 
kratom or to acute overdose cases [37,42,54]. The hepatotoxicity reports [54,95] are also very rare and 
mostly linked to long-term kratom consumption or to its excessive intake. 
2.1.3. Khat 
In the khat plant, many different substances have been found: alkaloyds, terpenoids, flavonoids, 
steroids, glycosids, tannins, amino acids, vitamins and minerals. The climatic conditions and 
environment determine a different chemical profile of the khat leaves. The major classes of alkaloids 
N
H
OCH3
N
OCH3H3COOC
N
H
OCH3
N
OCH3H3COOC
N
H
OCH3
N
OCH3H3COOC
N
H
OCH3
N
OCH3H3COOC
N
OCH3
N
OCH3H3COOC
Mitragynine Speciogynine
Paynantheine  Speciociliatine
7-Hydroxymitragynine
OH
H
HH
H
H
Figure 7. Chemical structures of the t i ole alkaloids in M. speciosa.
The ability of mitragynine to cause analgesic effects is linked to its interaction with supraspinal
µ- and δ-receptors [32,37,42,84], while the onset of stimulant activity is due to the block of the
stimulation of serotonergic 5-HT2A receptors and to the postsynaptic stimulation of the α-2 adrenergic
receptors [84,88]. The antinociceptive mechanism of the 7-hydroxymitragynine is, instead, linked to its
capacity of interaction with the µ-receptors, as shown by studies carried out on the tail-flick tests on
mice, and partially by the affinity with κ-opioid receptors [89]. Kong et al. [90] evaluated the effect of
the M. speciosa extract (MSE) on human recombinant cytochrome P450 enzymes: he observed that MSE
shows a high inhibitory effect on CYP3A4 and CYP2D6, whereas a moderate inhibition was found
for CYP1A2 and a weak inhibition for CYP2C19. These results suggest that the use of kratom could
cause dangerous consequences if consumed concomitantly with other drugs that are substrates of
the same enzymes. Many adverse effects are reported in the literature by several authors, including
fatal cases caused by co-consumption with other substances, like carisoprodol [88], modafinil [91],
propylhexedrine [92], Datura stramoniu [93], fentanyl [88], diphenhydramine, temazepam [94],
caffeine, morphine and O-desme hyltramadol [37,49,88].
However, th re are few studies in the lit rature proving the toxicity of kratom in humans. Seizure
episodes and withdrawal syndromes reported are mostly related t chronic consumption of kratom
or to acute overdose cases [37,42,54]. The hepatotoxicity reports [54,95] are also very rare and mostly
linked to long-term kratom consumption or to its excessive intake.
2.1.3. Khat
In the khat plant, many different substances have been found: alkaloyds, terpenoids, flavonoids,
steroids, glycosids, tannins, amino acids, vitamins and minerals. The climatic conditions and
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environment determine a different chemical profile of the khat leaves. The major classes of
alkaloids in the leaves are: cathedulins and phenylalkylamines. Cathedulins are based on a
euonyminol (1,2,3,4,6,8,9,13,14-nonahydroxydihydro-b-agarofuran) structure, which is esterified
with acids. In the leaves of khat, 62 species of different cathedulins were identified [96,97]. The
most important phenylalkylamines found in the leaves are (S)-cathinone, two diastereoisomers,
(1S,2S)-norpseudoephedrine (catina), (1R,2S)-norephedrine, and 1-phenyl-1,2-propanedione (probably
precursor of (S)-cathinone) [97–100]. The biosynthetic process is not well characterized in
plants but probably, the synthesis of (S)-cathinone starts with L-phenylalanine amino acid.
Cathine and (1R,2S)-norephedrine are obtained by means of the subsequent oxidation process of
(S)-cathinone [98,99]. This oxidation is obtained during ripening, because cathinone enters the young
leaves and its sprouts [99]. The foliage contains cathina and (1R,2S)-norephedrine approximately in a
ratio of 4:1 [101], other phenylalkylamine, merucathinone, pseudomerucathine and merucathine, are
present but they are secondary alkaloids with lower stimulant effects. Only in 1975 did the United
Nations laboratories identify (S)-cathinone as a principal constituent of khat, with a euphoric and
anorexic property [99,102]. Cathinone has a tendency to decompose shortly after harvest, forming
its dimer, 3,6-dimethyl-2,5-diphenylpyrazine, for this reason, consumers prefer to chew fresh leaves.
Figure 8 shows the chemical structures of the most abundant alkaloids present in leaves of Catha edulis,
whereas Figure 9 shows a dimer that is formed as a result of the decomposition of cathinone.
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lough et al. [16] carried out a study in the aboriginal population of the east rnhe Land
(northern ustralia). One hundred and one adults were recruited in the project, among which
38 (current kava users, four women and 34 men) reported to have used kava at least once during
the month preceding the interview. Nine women and 18 men, 27 in all, declared recent use and 36
(23 women and 13 men) reported to have never used kava. Among the kava users, the authors noticed
the follo ing significant alterations: a characteristic der opathy, elevation of γ-gluta yl-transferase
(γ- T) and alkaline phosphatase levels and a decrease in lymphocytes. Russmann et al. [103] described
the onset of two hepatitis cases with a marked elevation of transaminases and bilirubin after the intake
of traditional kava extracts. The dosage of kavalactones was known only in one patient: 18 g/week for
4–5 weeks. After observing that in 27 heavy kava users in New Caledonia there was an elevation of
γ-GT in 23 out of 27 and a minimal elevation of transaminases in eight out of 27, the authors concluded
that the traditional aqueous kava extracts could also be responsible for liver damage in rare cases.
The raise in γ-GT has been frequently described in literature in association with kava drinking [104].
However, the increase was found to be dose related and reversible after kava withdrawal. The γ-GT
elevation was observed by other authors [105] at an average ingestion of 310–440 g/week of kava
powder and Mathews et al. [15], found it to be greatly increased in very heavy kava users (mean
consumption, 440 g/week), while Bro n et al. [106] found γ-GT to be significantly high in chronic
kava intake in 65% of cases. However, the γ-GT elevation could also reflect enzymatic induction,
rather than hepatotoxicity. The clinical trials performed to examine the efficacy of kava did not show
hepatotoxicity. A meta-analysis by Pittler et al. [107] including seven clinical trials did not indicate the
occurrence of toxicity in the liver. Sarris et al. [108] performed a clinical trial on 60 participants who
had been suffering from generalized anxiety for a month or more, to assess the efficacy of an aqueous
kava product. The dose administered was of 250 mg of kavalactones per day for three weeks. No
serious adverse reactions were noticed, no clinical hepatotoxicity was observed in the study. The same
author [109] performed another controlled trial, administering 240 mg/kavalactones per day to the
patients (affected by generalized anxiety disorder) for six weeks, vs. a placebo group. No relevant
changes across groups were noticed in the liver function tests.
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that the alkaloids contained in the leaves may be the underlying reason that causes the hepatotoxicity
of the kava dietary supplements, as these may contain leaf material. They tested the following alkaloid:
PM showing that the exposure of HepG2 cells to 100 µM of PM determined 90% cell vitality loss in 24 h,
while an exposure to 50 µM caused a 65% viability loss in the cells. Similar amounts of the following
kavalactones, DMY and DHM, did not distress cell viability, even if administered for eight days.
Moreover, the authors noticed that PM was able to decrease ATP levels in cells, to reduce mitochondrial
membrane potential and to induce apoptosis (release of caspase-3). However, PM was not detected in
a series of products containing kava in the German market [70,111,112]. Other authors [113] evaluated
the hepatotoxicity of kavain, M and yangonin in vitro on HepG2 cells. Cytotoxicity was established by
the use of the following assays: lactate dehydrogenase (LDH) and ethidium bromide (EB). Moreover,
cell death pattern was evaluated in fluorescence microscopy, and an ortho-phthalaldehyde (OPT)
fluorescence assay was used to measure glutathione (GSH) oxidation. Among the three compounds,
kavain was found to be slightly cytotoxic, while M displayed moderate toxicity depending on the
dose (cell vitality decreased to almost 75% at the concentration of 200 µM). Yangonin showed the
most marked effects determining 40% of reduction in cell vitality at the concentration of 25 µM.
After evaluation with fluorescence microscopy, it was found that the predominant death model was
apoptosis rather than necrosis. Zhou et al. [114] examined the toxicity of several kava constituents
on HepG2 cells. Experiments, carried out exposing cells to the major kavalactones did not show
toxicity at a concentration up to 150 µM, excepting for yangonin, which exhibited a weak cytotoxic
effect. On the contrary, the three chalcones (FKA, B and C) displayed important cell death at a
concentration ranging from 10 to 50 µM. Flavokawain B (FKB) was found to be the most powerful
toxin. All the compounds were also tested on a non-tumor origin immortalized human liver cell line
(L-02) and only FKB and flavokawain C (FKC) were able to determine cell death in this specific cell
type. Therefore the authors demonstrated that FKB is a strong hepatocellular toxin, its mechanism
of action is displayed through oxidative stress induction, GSH depletion, by the inhibition of NF-κB
transcription in vitro and in vivo (its activity is crucial in protecting liver cells during their development
and survival). Moreover, it causes the constitutive TNFα-independent stimulation of protein kinase
(MAPK) signaling pathways (ERK, JNK and p38). The transitory activation of the latter causes
proliferation, whereas prolonged activation of JNK is linked to hepatocytic death. The administration
of exogenous GSH rescued hepatocytes from FKB induced death. Lüde et al. [115] studied the
effects of three kava preparations, an acetonic and methanolic root extract and a leaf extract in
methanol, on rat liver mitochondria and HepG2 cells. Each preparation showed cytotoxicity starting
at a concentration of 50 µg/mL for the lactate dehydrogenase leakage test and of 1 µg/mL for the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. Apoptosis was induced by
the three extracts at the concentration of 150 µg/mL. The results showed that kava extracts are toxic
for the mitochondria, inhibiting the respiratory chain, decreasing mitochondrial membrane potential
and increasing reactive oxygen species (ROS) production. Jhoo et al. [116] evaluated the cytotoxicity
based on LDH, MTT, and aspartate aminotransferase (AST) enzyme leakage assay techniques on
HepG2 cells, of kava (root, stem peeling and leaves) extracts (with methanol). The residues underwent
partition with solvents of different polarities “hexane, ethyl acetate, n-butanol, and water”. The
fraction exhibiting the highest cytotoxic effects was the hexane fraction of the root. Fractions extracted
with organic solvents displayed greater toxicity in comparison with the water extracts. Further
analysis on the hexane fraction revealed that the molecule responsible for cytotoxicity was FKB. Other
authors [117] investigated the effects of the latter molecule on leiomyosarcoma (LMS) cell growth,
to examine its effectiveness in the management of uterine LMS. Three different cell lines were used:
endometrial adenocarcinoma (ECC-1), uterine leiomyosarcoma (SK-LMS-1), and human endometrium
fibroblast-like (T-HESC) (non-malignant). The cells were exposed to different concentrations of FKB,
and subsequently apoptosis, cell cycle and viability were evaluated. FKB selectively inhibited the
growth and induced apoptosis in ECC-1 and SK-LMS-1 cell lines in comparison with T-HESC control
cells. FKB was able to arrest the cell cycle and to induce apoptosis in ECC-1 and SK-LMS-1 cell
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lines, for these reasons it is suggested to be a potential therapeutic instrument for the handling of
uterine LMS. Other authors [118] investigated the toxicity of kava, alone or in combination with
acetaminophen (APAP) in an animal study on mice. The administration of kava alone did not cause
adverse effects, even if it was administered at the dosage of 500 mg/kg, for a long period of time
(six days a week ˆ 14 weeks), while pretreatment with kava for three days, heightened APAP-induced
hepatotoxicity, resulting in alanine aminotransferase (ALT) and AST elevation in serum and an
enhanced severity of lesions in the liver. The authors also investigated the effects of the chalcones
FKA and FKB and DHM (kavalactones group). The two chalcones demonstrated a synergism of action
with APAP in the damaging of the liver, while DHM had no such outcome. Therefore, the authors
hypothesized that flavokawains played a central role in liver damage, highlighting moreover, that
usually these compounds are not abundant in the traditionally utilized cultivars of kava unlike the
cultivars that are not recommended for traditional use. Moreover, an analysis performed by the same
authors on a set of kava products showed that the amount of FKA and FKB is characterized by a great
variability („20-fold) [119]. Additionally they evaluated the variability in chemical composition of the
extract and the cytotoxicity of 25 kava products, performing a study on human lung adenocarcinoma
cells (A549). The results revealed great variability on both the chemical composition and toxic effects
on cells. Other authors [120] assessed the presence and the amount of FK (A, B and C) in different
cultivars of kava (wichmannii-wild, medicinal, noble and “two-days”) concluding that the ratio between
FKB and kavalactones is higher in two-days than in the wichmannii cultivars of kava, 0.39 and 0.32,
respectively, while noble and medicinal cultivars showed a ratio of 0.09 and 0.10, respectively. The kava
plant chalcone, FKA and other kava constituents have been investigated in several toxicity studies as
chemotherapeutic agents because in countries where the use of traditional kava use is widespread, the
incidence of cancer is lower than in other countries. Therefore Li. and colleagues [121] performed a
systematic determination of FKA safety on mice. The animal diet was supplemented with 0.6% of FKA
or 0.6% kava root extract (KRE) for three weeks. After histopathological investigation of the organs
(thymus, kidney, liver, colon, lung, spleen and heart), no signs of toxicity due to FKA were noticed,
but there was a KRE diet supplement induced nodular liver proliferation. Other authors [111] did
not notice liver injury or any enhancement of galactosamine-induced hepatitis after administering
kava (aqueous and organic solvents extracts) to rats at the following doses: 31.25, 62.5 and 133 mg/kg
diet for three months. This result is in accordance with a former study of Singh and Devkota [122]
performed using the aqueous kava extract. Moreover, Sorrentino and colleagues [26] did not notice
liver toxicity after the administration of 7.3 or 73 mg/kg of kava extract (ethanolic) to rats for three
and six months. The administration for 14 weeks to rats via gavage of kava extracts (at the following
concentrations: 0, 0.125, 0.25, 0.5, 1.0, and 2.0 g/kg/day, five days a week) performed by the National
Toxicology Program (NTP) 2007 [123] showed the following results: a raise in γ-GT was noticed in
the rats in which the extracts were administrated with a concentration of 2.0 g/kg (males) and from
1.0 up to 2.0 g/kg (females); elevation in serum cholesterol levels in both males and females starting
from the dose of 0.5 g/kg; heightened frequency and severity of hepatocellular hypertrophy (HP);
and increased liver weight (starting from the dosage of 1.0 g/kg for males and 0.5 g/kg for females).
Therefore, the authors highlighted that the value of 0.25 g/kg is the level in which no adverse effects
are observed. However, it was also noticed that the incidence ratio of kava-associated hepatotoxicity in
humans is really low (0.008/1,000,000 daily doses), whereas the frequency of benzodiazepine-related
hepatotoxicity is much higher (bromazepam 0.90, oxazepam 1.23 and diazepam 2.12) [124,125].
Carcinogenicity, Mutagenicity and Toxicity
Whittaker et al. [126] evaluated the mutagenicity and toxicity of the two commercial products
of kava together with the six major kavalactones on mouse lymphoma cells (L5178Y) with pooled
human liver S9 and no mutagenic reaction was observed. The most toxic results were obtained
with yangonin and DMY at the following doses, 0.5–20 µg/mL and 1.25–20 µg/mL, respectively.
Behl et al. [127] studied the effects of kava administration in rats and mice via gavage for two weeks,
Int. J. Mol. Sci. 2016, 17, 580 13 of 30
13 weeks and two years. It was shown that the administration of kava at 0.125 to 2 g/kg in pre-chronic
studies could determine an increase in liver weight according to the dose, and an elevation in the
frequency of hepatocellular hypertrophy (HH), while in the chronic management, the incidence of
HH increased up to 1 g/kg body weight, moreover centrilobular fatty change accompanied HH. No
increase in carcinogenesis was observed in the livers of rats, while in male mice an elevation in the
frequency of hepatoblastomas (dose-related) was noticed. In female mice, hepatocellular carcinoma
and adenoma were increased, however not in the high dose group but in the mid and low dose groups.
Moreover, numerous non-neoplastic lesions were found in the livers. Another study performed in
2012 [128] confirmed a remarkable increase in liver cancer in mice of both sexes and the occurrence of
non-malignant lesions in the liver, such as HH. Moreover, kava extracts may determine an increase in
testicular tumors in rats.
Glutathione (GSH) Depletion, Enzymatic Polymorphisms and Cyclooxygenase-Inhibition
Yang et al. [129] co-treated rat primary hepatocytes with kava and Acetaminophen (APAP) the
co-administration determined 100% loss in cell vitality while treatment with the substances alone
determined 50% of loss with APAP and 30% with kava. The reduction in GSH due to APAP was
furthermore potentiated by kava. Cellular ATP content and the potential of mitochondrial membrane
decreased after the co-exposure. The production or reactive oxygen species (ROS) was found to be
higher. Li et al. [8] investigated hepatotoxicity mechanisms underlying kava and alcohol intake, as
the two substances are frequently co-ingested. The authors suggest a paracetamol-like mechanism of
hepatotoxicity for kavalactones, as both molecules are able to determine GSH depletion, moreover
they cause CYP2E1 induction, up to 3–4-fold [130], during chronic alcohol intake. The consequent
metabolism through this cytochrome, could cause the formation of reactive compounds. The latter
could additionally mediate immune toxicity via the production of protein adducts, which function
as neo-antigens leading to idiosyncratic responses. Moreover, as suggested by Li [131], several
xenobiotics, able to determine immune-related hepatotoxicity, undergo activation through CYP 2C9,
2E1, and 3A. The authors [8] conclude that chronic alcohol intake together with the ingestion of
kavalactones, may speed up the production of reactive metabolites with a consequent higher risk of
hepatotoxicity. Whitton et al. [71], studied the effects of kavalactones alone or in combination with
GSH, incubating at 34 ˝C amoeba cells for seven days. The 100% of the cells incubated only with
kavalactones (100 mg¨mL´1) died, while the 60% of amoeba cells incubated also with GSH, survived
after the treatment. Therefore, GSH provides protection against the damages due to kavalactones, via
Michael reaction, which results in the opening of the lactone ring rendering it non-toxic for eukaryotic
cells. Usually, these substances would therefore be detoxified through the conjugation of GSH to
the lactone and across CYP2D6 (main metabolic pathways for kavalactones are demethylation of the
alpha-pyrone ring system (4-methoxyl group) and/or reduction (of 3,4-double bond) [132], for this
reason individuals with a deficit in CYP2D6 could suffer from liver damage after kava ingestion [133].
However, liver injuries could be prevented by the intake of an excess of GSH. The authors
conclude that in all traditional kava preparations the availability of GSH (ratio 1:1 with kavalactones)
counterbalances the presence of kavalactones while western extracts are relatively deprived of GSH.
Moreover CYP2D6 poor metabolizers, undergoing kava-related hepatotoxicity were described by
Russmann et al. [134]. Interestingly only 1% of Pacific/Asian islanders are poor metabolizers of this
Cytochrome, compared to 12%–21% of Caucasians [135]. This fact could explain the lower incidence of
kava-related hepatotoxicity in the Pacific islands. Aghdassi et al. [136] identified four patients who
underwent acute liver failure after the intake of kava-kava, administered for mild depression. Three of
the patients needed liver transplantation and only one of them had previously taken other medications
(piretanide and etilefrine). As the polymorphism of the gene CYP2D6 (poor metabolizer) has been
related to a higher probability of developing kava-induced hepatotoxicity [134] and, moreover, herbal
products such as kava, can determine an inhibition in the catalytic activity of CYP2C19, the authors
have investigated uridine diphosphate glucuronosyltransferase (UGT1A7) gene variations. The authors
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hypothesized that as kavalactones are excreted via the urine for more than 50%, glucuronidation may
be a major elimination pathway for Piper methysticum metabolites. The authors concluded that the
allele frequency of the uridine diphosphate glucuronosyltransferase isoform UGT1A7*3 (characterized
by low enzymatic activity) was higher in the patients, compared to the allele frequency in Caucasians;
moreover, one of the patients needing transplant was found to be homozygous. No CYP2D6 decrease
in activity was assessed because no poor metabolizer phenotype was detected for this enzyme. In
reply [27] to the previously reported study, Stickel highlighted that caution is needed when claiming
an association, having analyzed only a limited case series of four patients. Also cyclooxygenase-1 and
2 (COX-1 and COX-2) inhibition could be responsible for kava hepatotoxicity [137], since yangonin
and dihydrokavain inhibit these enzymes at the concentration of 100 µg/mL. Another study [138]
demonstrated that kava inhibits COX-2 selectively. These effects would commonly be associated with
benefits and antioxidant properties, however according to other authors, hepatotoxicity is not an
unusual finding after exposure to drugs that inhibit COX [72].
P450 Activity Alteration
Mathews et al. [139] evaluated the inhibition potential of the whole kava extract (100 µM total
kavalactones) on human liver microsomes (HLMs). A decrease in P450 activities associated with
the concentration was noticed. A substantial inhibition in the activity of the following CYP was
detected: CYP2C9 (92%), 2C19 (86%), 1A2 (56% inhibition), 2D6 (73%), 3A4 (78%), 4A9/11 (65%)
after the pre-incubation with HLMs and NADPH for 15 min. The incubation with kawain did not
alter enzymatic activity while DMY inhibited CYP2C9 substantially (42%), M (58%), and DHM (69%)
at 10 µM. Moreover, the latter molecules could inhibit CYP2C19 (DHM 76%), CYP2D6 (M 44%)
and CYP3A4 (DMY 40%, M 27%, and DHM 54%). These findings show that kava is extremely
likely to determine drug interactions through its inhibition of CYP450 enzymes. Another in vitro
experiment [140] performed on cryopreserved human hepatocytes and on cDNA-expressed human
enzymes, revealed that the kava extract is a powerful inhibitor of CYP 1A2, 2C9, 2C19, 2E1, and
3A4. Moreover, the compounds displayed moderate cytotoxicity on human hepatocytes. M, exhibited
more potent cytotoxic effect and inhibition activity followed by kava root extract, DMY, and yangonin.
Different extracts of kava were likened to evaluate their inhibition potency on major drug metabolizing
P450 enzymes on human liver supersomes and microsomes by Côté et al. in 2004 [141]. Inhibition
in activity was noticed for CYP3A4, 1A2, 2C9, and 2C19. The inhibition was more marked in the
commercial preparation while the aqueous extract was found to be less potent. Mathews et al. [142]
performed experiments in vivo and in vitro to evaluate the effects on CYP450 and on P-glycoprotein
activity due to kava extracts and kavalactones. Oral pharmacokinetics of kawain were also assessed
in rats. Kawain underwent extensive absorption and was eliminated (>90% of the dose) within
72 h mainly in urine. A seven-day pre-treatment with kava (391 mg/kg) induced a significant
increase (35%) in Hepatic P450 content. The activities of the following cytochromes, CYP1A2, 2B1,
and 2C6, were heightened about 200% in comparison with control animals. An increase (51%–80%)
in the activity of CYP3A1/2 was also noticed, while the activities of CYP2D1 (human CYP2D6
homologue) and CYP2C11 were reduced (25% and 77%, respectively). In vitro experiments on human
hepatic microsomes showed inhibition of CYP2C9, CYP2C19, CYP2D6 and CYP3A4. There was a
modest stimulation of P-glycoprotein activity. Another study performed on rats [143] was carried
out administering PM 10 mg/kg and kava root/rhizome extracts (KRE) 100 mg/kg (acetone/water
extracts) for fifteen days. This treatment did not cause any substantial alterations in liver weight, liver
function tests, nor any important hepatic toxicity was noticed through measuring anti-apoptotic protein
Bcl-2, Bax pro-apoptotic protein and malondialdehyde (MDA) as apoptosis and lipid peroxidation
markers. Nevertheless, rats treated with PM showed changes suggesting adaptive response to oxidative
stress (rise in TNFα mRNA expression, hepatic GSH, cytosolic superoxide dismutase-Cu/ZnSOD
and increase in CYP1A2, CYP2E1). Guo et al. [144] studied the effects of kava administration via
gavage for 14 weeks in male rats to evaluate the changes in the expression of gene encoding for drug
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metabolism enzymes. In the high-dosage treatment groups 16 genes were found to be altered. CYP3A1,
3A3, 1A1, 1A2, and 2C6 expression increased, while CYP 2C40 and 2C23 decreased in rat livers. The
changes in expression were found to be dependent on the dose. Yamazaki et al. [145] investigated
the effects on the gene expression of CYP1A hepatic isoforms in rats, following the administration
of kava products for eight days (380 mg/kg/day kavalactones). CYP1A is probably involved in the
activation of carcinogens such as aflatoxin and benzo(a)pyrene. After the treatment, liver weight
increased significantly. A moderate rise in CYP1A2 mRNA expression was observed, while CYP1A1
mRNA expression was found to be markedly enhanced (75–220-fold). Guo and colleagues [146]
investigated the gene expression profile in male mice livers following the administration via gavage
of kava extracts for 14 weeks. An alteration in oxidative stress response Nrf-2 mediated as well
as mitochondrial activity were noticed. Additionally, the levels of a substantial number of genes
involved in drug metabolism and xenobiotic metabolism pathways were altered. 29 Phase II genes,
38 transporters genes and 28 Phase I metabolizing enzymes genes were found to be significantly
changed in their expression after kava intake. Major gene expression alterations were noticed on
the following: CYP1a1, CYP1a2, Gstal, Gsta2, CYP2b20, CYP2a5, CYP3a11 and CYP2c55. This fact
could lead to potential hepatotoxicity through the interaction between drugs, herbs and modulation of
metabolism. After the administration via gavage of kava extracts for 14 weeks to rats, it was shown
through immunohistochemical analysis that CYP-450 expression in 2.0 g/kg treated females had
decreased for the homolog of CYP2D6 [123]. Moreover, a raise in the expression of CYP1A2, 2B1, 3A1
was noticed in 1.0 and 2.0 g/kg treatment groups (males and females). Alteration of CYP450 activity
can determine herb drug interactions leading to toxicity, in fact several hepatotoxicity cases included
co-ingestion of other drugs or herbal remedies. Moreover, as the inhibition potential is dissimilar in
the different compounds, and furthermore the composition in kavalactones and other constituents
is highly variable, depending on extraction procedure and raw material, divergent effects can be
expected after the intake of different kava preparations.
Reactive Metabolites
Hepatotoxicity could also be mediated through the formation of reactive kavalactones metabolites
including 6-phenyl-3-hexen-2-one [147]. It was found to be highly reactive in vitro. In vivo, the
formation of mercapturic acid-conjugates was assessed in the urine of two volunteers after a single
dose of powdered kava root (10 g). Moreover, the generation of electrophilic intermediates, such
as 11,12-dihydroxykavain-o-quinone and 11,12-dihydroxy-7,8-dihydrokavaino-quinone, has been
demonstrated by Johnson et al. [148], after in vitro incubation of kava extracts with NADPH, GSH and
hepatic microsomes. These products could interact binding to DNA or through alkylation and linkage
to hepatic proteins. The mercapturic acids of these species (quinoid) were not detected in human
urine after the ingestion of kava. This fact could lead to the conclusion that although the formation
in vitro of quinoid metabolites has been observed, these compounds are not formed in considerable
amounts after the intake of modest doses of kava products. The resultant catechols (dihydroxylated
derivatives) were conjugated extensively with sulfate and glucuronic acid and were detected in human
urine. The impact of quinoid metabolites could be relevant, and therefore contribute to hepatotoxicity
in vivo, in case of saturation of conjugation pathways or for the alteration of metabolic routes. Other
authors [149], after examining the in vitro metabolism of flavokawains, highlight that the chalcone
metabolite conjugates could presumably be active in vivo, and that currently these metabolites are not
included in routine testing.
Mould Hepatotoxins and Contaminants
Teschke et al. [70] performed a review focusing on PM, flavokavain B and mould hepatotoxins
as possibly being responsible for this toxicity. The authors noticed a lack of evidence regarding the
two first compounds. The weather that characterizes the Pacific islands (warm and humid) is likely
to determine the development of mold (such as aflatoxins or others) during storage. Moreover, kava
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material may be contaminated by pesticides, fertilizers, oil, bacteria, fungi, etc. The authors suggest
performing further studies on this topic. This hypothesis has led to a lively debate [150,151].
Inflammation
Zhang et al. [152] highlighted the presence of hepatic inflammation (as described in literature) in
cases of kava intake and kava-associated toxicity. The authors suggest direct inflammation through the
action of more than 40 molecules isolated from kava, among which: kavalactones, the toxic alkaloid PM
and the chalcone FKB, highly toxic. Otherwise, the inflammation could be due to indirect mechanisms
such as the reduction of liver GSH or to the effects of toxic metabolites. Therefore, the same authors
published a study in 2012 [153] highlighting the potential engagement of liver macrophages in the
development of toxic damage to the liver. Experiments carried out on isolated perfused rat livers,
showed that hepatic sinusoids undergoing treatment with kavalactones, displayed extensive injuries,
while if pretreated with gadolinium chloride (macrophage intoxicant) no damage was noticed.
Kava Hepatotoxicity Reports
Several hepatotoxicity cases are reported in literature. The first cases were described in 1998 [28].
Gow et al. [154] described in 2002 the case of a 56-year-old woman admitted to hospital in Melbourne
for increasing jaundice that lasted for two weeks and was accompanied by nausea and fatigue. She had
been taking an herbal supplement to treat anxiety for three months. The herbal remedy contained 60 mg
of kavalactones as well as Scutellaria Laterifloria 100 mg and Passiflora Incarnata 50 mg. Viral tests
for hepatitis, cytomegalovirus and Epstein Barr were all negative. Wilson’s disease and paracetamol
intake were also excluded. The patient’s condition worsened and she underwent liver transplantation,
but after the operation she died of massive bleeding. The explanted liver histological examination
revealed considerable hepatic necrosis. Another case was described by Escher et al. [155]. A 50-year-old
man experienced fatigue, dark urine and darkened skin for about a month, before going to the doctor
with jaundice. Although the patient’s medical history was unexceptional and he did not use alcohol
or other drugs, he suffered from anxiety, and, for this reason, he took kava extracts (3–4 capsules
a day, 210–280 mg of lactones cumulatively) for two months. After undergoing liver transplant,
he recovered. Campo and colleagues [156] reported the case of a 14-year-old girl who successfully
underwent liver transplantation for fulminant hepatitis after an intake of commercial kava products
for three months, while other authors [157] performed a retrospective case series on patients admitted
to the liver transplantation unit, describing a high incidence of fulminant hepatic failure among dietary
supplements users. They identified three patients who underwent liver transplant after the intake
of kava, alone or in association with Ma Huang or Chaparral. Stickel and colleagues [158] analyzed
29 cases of hepatitis following kava intake, reported to the German Department of Pharmacovigilance
from 1990 to 2002. Moreover, the authors evaluated seven cases previously described in literature,
they concluded that the greater part of the patients were female, hepatic damage (cholestatic hepatitis
or hepatic necrosis) occurred equally with both acetonic and alcoholic kava extracts. In addition, the
latency of the toxic reaction onset and the cumulative dosage were decidedly variable. Nine patients
needed liver transplant because of fulminant hepatic failure, three of them died and the others all
recovered after eliminating kava use. The authors hypothesize idiosyncratic and immune-allergic
factors to be responsible for kava hepatic damages. Another case is reported by Humberston et al. [159]
involving a 14-year-old teenager undergoing liver transplant after the use of kava products for four
months. Teschke et al. [160], highlighted that, if the 19 suspected hepatotoxicity cases supposed to be
due to kava intake in Germany had been evaluated more critically, the causality in these cases would
have been attributed only to one patient. Possible causality could be endorsed for another patient,
unlikely/excluded for five patients and insufficient data for 12. Moreover, the case of a 42-year old
male who had toxic hepatitis caused by consuming traditional kava products (2 to 3 L cumulative
volume) in the Samoan islands, was reported by Christl et al. [161]. Fortunately, the patient recovered.
Int. J. Mol. Sci. 2016, 17, 580 17 of 30
Up to 2002, 82 cases in total of hepatotoxicity possibly linked to kava are available from different
databases. Amongst the cases evaluated by Schmidt [125], 20 had no relationship with kava intake,
21 cases were characterized by concomitant treatment with potential hepatotoxic substances, 31 were
characterized by insufficient data and in seven cases there was substantial doubt in considering the
causality of kava. Amid these, three were possibly associated to kava. Clouatre [72] suggests that the
direct toxicity of kava is small, however the possibility it determines drug interaction or heightens the
toxicity of other drugs is huge and kava toxicity seems to be due to idiosyncratic reaction. However,
at least three major mechanisms of hepatotoxicity are enumerated in literature: GSH reduction in
liver, cyclooxygenase and CYP450 inhibition. Nevertheless, if every kava hepatotoxicity reported
case were to be attributed to kava intake, the rate of adverse reactions as calculated by Schmidt [125]
may be 0.3 cases/1,000,000 daily doses, therefore kava would display a better risk-to-benefit ratio in
comparison with benzodiazepines.
Schmidt et al. examined once more kava hepatotoxicity reports up to 2003 [124], as listed by
several health authorities among which: EMEA, FDA, BfArM, IKS, Therapeutic Goods Administration
(Australia) and from literature. Only three cases could be attributed to kava intake with high probability,
two were related to kava overdose. Therefore, kava induced-hepatotoxicity should be really rare,
and the authors highlight the fact that, as drug induced hepatotoxicity frequency ranges from 1
to 10 per 100,000 exposed individuals, kava would be under one, even if all the cases of reported
toxicity were causally linked to kava intake.
2.2.2. Kratom
Toxicity Studies in Cell Lines and in Animal Models
To date, there is scarce information about the toxicity of M. speciosa alkaloid extracts and little is
known about the adverse effects that have really originated from mitragynine intake. The M. speciosa
cytotoxicity has been evaluated by three authors in different cell lines [162], brine shrimp [163] and
gene mutation assays [164]. Saidin [162] tested the cytotoxicity both of the methanol-chloroform
extract (MSE) and of mitragynine (MIT), on human cell lines (HepG2, HEK 293, MCL-5, cHol, and
SH-SY5Y). The MSE inhibited cell proliferation in all cell lines, depending on the dose administered,
inducing cell death at 1000 µg/mL and MIT showed a similar model of action. Even if the activated
pathways that led to cell death were different (MSE cell death seemed not to be associated with
p53 and caspases pathway, contrary to that caused by MIT), the results of these studies suggest that
both the methanol–chloroform extract and its dominant alkaloid mitragynine, generate cytotoxicity
effects at doses higher than 100 µg/mL. In a brine shrimp lethality test, Moklas et al. [163], evaluated
the toxicity level of three different preparations of mitragynine: the authors found that the LC50 for
the aqueous extract was 98 µL/mL, the crude alkaloid extract exhibited a LC50 value of 62 µL/mL,
while mitragynine showed the high toxicity with LC50 of 44 µL/mL. The potential of mutagenic and
antimutagenic activity of M. speciosa was evaluated by Ghazali et al. [164], incubating the aqueous
extract of the plant with Salmonella typhimurium TA 98 and TA 100 bacterial strains, in presence and
absence of the metabolic activator S9 system. The Ames test (Salmonella/microsome mutagenicity
assay) showed no mutagenic activities for M. speciosa both in presence and in absence of the metabolic
activator, and with both bacterial strains, but, in the same experimental conditions, M. speciosa had
a strong antimutagenic property. Several studies were carried out in animal models to evaluate the
toxicity of the mitragynine, Macko et al. [165] in 1972, tested, for the first time, mitragynine toxicity in
rats and dogs: he found no adverse effects in rats up to a dose of 40 mg/kg/day six days per week,
until the twenty-second day of treatment, when hematological alterations were observed, on the other
hand, no toxicity signs were noticed in a group of dogs treated with an oral dose of 5 mg/kg/day
of mitragynine for three weeks [52]. Recently, Sabetghadam et al. [53] investigated the sub-chronic
exposure to mitragynine of male and female rats, administering oral doses of 1, 10, or 100 mg/kg
for 28 days. At the lower doses, there was no evidence of toxic effects (such as tremors or seizures),
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whereas at a dose of 100 mg/kg, alterations in food intake emerged, with a consequent strong decrease
in weight especially in female rats. No deaths occurred at the maximum dosage. Hematological,
biochemical analysis and histopathological examination of the brain, kidneys and liver were performed.
With regard to the hematological findings, the authors observed a severe anemia, characterized by
a decrease in the red and white blood cells, a reduction of the hematocrit levels with a lowering
of the hemoglobin content. Signs of tissue toxicity were observed in the histopathological analysis
performed on the brain, kidney and liver. Local vacuolation and the presence of degenerated necrotic
neurons were noticed in the brain; in the kidneys an early state of nephrotoxicity was observed. These
findings were highlighted in all the animals exposed to the maximum dosage of mitragynine, in
particular in female rats. The alteration of some biochemical parameters corresponded to the structural
modifications discovered in the liver. Very high levels of serum lactate dehydrogenase, aspartate
aminotransferase (AST), alanine aminotransferase (ALT) and urea, indices of hepatocellular damage,
were observed; there was also an increase in liver weight of all the animals exposed to the maximum
dose of mitragynine. The histological liver examination showed moderate destruction of polygonal
lobules, dilation of sinusoids and hemorrhagic hepatocytes; there were no signs of centrilobular
necrosis or inflammatory cell infiltration. An increase in triglycerides, cholesterol, AST and ALT values,
albumin (indices of hepatic impairment), and the presence of histological evidence for hepatic cellular
damages, were also observed by Harizal et al. [45] after acute oral administration of 1000 mg/kg of
methanolic extract of M. speciosa in rats. In all the rats of the treated group, the histological analysis
revealed a severe hepatotoxicity, with a major number of Kupffer cells, hemorrhagic hepatocytes,
sinusoids congestion, steatosis and centrilobular necrosis. These studies show that the sub-chronic
dosages (1–10 mg/kg) of mitragynine in rats, which in humans corresponds to a dose of 0.1 to
1.7 mg/kg, seems to be quite safe when compared to those consumed by kratom users: in fact, the
content of kratom juice regularly consumed in the northern regions of the Malaysia Peninsular, is
equal to approximately 0.3 to 5.1 mg/kg per day and users do not show any side effects related to the
chronic use of this substance, as reported by Vicknasingam et al. [41,52].
As mitragynine has proved to be extremely toxic in rats, when administered for a prolonged period
at 100 mg/kg, in the future more studies must be carried out on the chronic exposure to mitragynine in
more complex living systems with dosages relevant for humans, in order to ascertain the possible link
between this substance and the severe hepatotoxicity observed in some of the researches here reported.
Kratom Hepatotoxicity Reports in Literature
Literature reports about mitragynine toxicity in humans are rare, even if in recent years clinical
cases are increasing. Only two papers have reported cases of hepatotoxicity secondary to kratom
consumption. The first case was published by Kapp et al. [54] in 2011: they described the case of a
25-year-old man, who after taking kratom for two weeks showed the onset of jaundice and itching.
He had started to consume one/two teaspoons of kratom (each teaspoon is approximately 2.3–3.5 g)
twice daily, increasing the intake up to four/six teaspoons daily. He interrupted the intake because
of swallowing problems, fever and chills and on the fifth day after stopping kratom, he developed
severe abdominal pain with the appearance of brown urine, jaundice and itching and was admitted to
hospital. The laboratory tests showed elevated values of transaminases, direct bilirubin and alkaline
phosphatase: the autoimmune analysis together with the antinuclear antibodies (ANA) test and viral
tests for hepatitis were all negative and no further drugs or medications were found. A computed
tomography of the abdomen was performed and it showed liver steatosis, without dilation of intra and
extrahepatic bile duct, while a liver biopsy revealed the presence of a pure cholestatic injury with bile
precipitations and fat vacuoles without hepatocellular damages. Distended and hyperemic sinusoids
were observed with signs of inflammation, which led to the diagnosis of canalicular cholestasis.
Toxicological analysis were performed in LC-MS with a linear ion trap, on both serum and urine
of the patient to detect the main alkaloids of mitragynine and its metabolites: samples of kratom
powder found in his home were also analyzed to exclude the presence of contaminants or adulterants.
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Despite more than two weeks had passed from the kratom discontinuation, as stated by the patient,
mitragynine and its main metabolites were detected in the urine sample. Whereas the data available
on mitragynine half-life are exclusively related to rats (4–9 h after a single dose) [166,167], the presence
of the substance and its metabolites in biological samples (serum and urine) of the patient may be
related to a serious prolongation of the alkaloids half-life that could be the consequence of the hepatic
injury or to the delayed clearance caused by the extensive first-pass hepatic metabolism. Due to the
lack of scientific data on the toxicity of kratom in humans, the physicians could not directly correlate
the onset of acute liver disease with the intake of kratom. The effects of the substances contained in
M. speciosa extract (alkaloids, saponins, flavonoids, etc.) have not yet been well researched making
the correlation between the health of the liver and the intake of these preparations very difficult: for
example only recently Azizi et al. [168] demonstrated a correlation between the administration of
M. speciosa extracts in mice and the increased level of glutathione-S-transferase, as a possible sign of
hepatic disease. The second case report was described by Dorman et al. [95] in 2015: a 58 year old
man was admitted to hospital with jaundice and dark urine after prolonged daily kratom intake. He
had also consumed other medications, for more than two years, including quetiapine (100 mg/day)
and sertraline (50 mg/day). Biochemical analysis revealed a total bilirubin of 25.6 mg/dL, alanine
transferase (ALT) 106 U/L, aspartate aminotrasferase (AST) 49 U/L and alkaline phosphatase (ALP)
790 U/L with a R ratio of 0.24 that indicated cholestatic injury. The antinuclear and the smooth muscle
antibodies tests were negative as were the viral tests for hepatitis A, B and C. The ultrasound analysis
of the abdomen revealed only an irregular hepatic texture without signs of biliary obstruction and a
hepatic biopsy was not performed. The authors defined idiosyncratic the onset of liver complication
but evaluated as “convincing” its association with the intake of kratom.
2.2.3. Khat
Hepatotoxicity
Toennes et al. [59], has studied the pharmacokinetics of khat in four subjects and the results
suggest that chewing it, is very effective. The buccal mucosa plays a very important role in the
absorption of cathinone, cathine and norephedrine. Only 10% was found in the leaves chewed. The
amount of norephedrine found in urine was higher than the amount ingested. Only 7% of cathinone
was excreted in the urine. In this experiment, a single administration (0.6 g/kg) was given; normally
consumers chew 100–300 g of leaves in a period of 3–4 h [59,169,170]. In the United Kingdom, khat
is legal and cheap, this is why the use of this substance is very high, especially among Somalis who
live in the UK [65]. In the literature, there are an increasing number of cases of severe liver injury as
a consequence of khat use or abuse, in particular in the UK, Holland and other European countries
where Catha edulis is legal. In many cases, a common factor is the occurrence of non-viral hepatitis
with khat uses. Roelandt et al. describe a case of a 26-year-old Somali man, living in the UK, with
secondary acute liver failure. Having excluded all other possible causes such as tumoral invasion,
vascular or biliary complications, nodules, cholecystolithiasis, steatosis and hepatitis and the absence
of alcohol, medication, dietary supplements, herbs, or illicit drug abuse, apart from khat, a liver
transplant was deemed necessary [65]. Six other patients in the UK, with an age ranging from 24 to
57 years, five Somalis and one Yemen, were affected with acute hepatitis. Patients followed a treatment
with prednisolone and responded well to immunosuppression. All of these had a history of khat
use. In evaluating diverse parameters, such as liver enzymes, autoimmune screen, exclusion of viral
hepatitis alcohol and drugs, immunoglobulin levels and liver histology, Riyaz et al. [64] suspected that
khat could possibly cause the onset of autoimmune hepatitis, in genetically susceptible subjects. It
will be necessary to conduct further studies in order to confirm this hypothesis. In the case report of
Yildiz et al. [66], a 25-year-old male Somali, ex-consumer of khat, went to a medical center with jaundice
and hepatitis, which was negative to viral hepatitis A, B and C, but positive to ANA (Antinuclear
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antibodies) and anti-actina antibodies, even though the biopsy showed a compatibility with toxic
hepatitis, it was more similar to autoimmune hepatitis for the serum parameters.
Chapman et al. [171] presented six patients from the UK who were khat abusers and had reported
severe liver injury, four underwent a liver transplant, and two died. Abid et al. investigated whether
or not khat induces apoptosis in the L02 human hepatic cell line with the result that khat does indeed
induce significant apoptosis of cultured cells L02 [172].
Inhibiting Action
The enzymes implicated in metabolism of khat have not yet been described. It is supposed that
P450 (CYP) is involved because many recent studies have identified CYP2D6, as the enzyme included
in the metabolism of syntethic cathinone derivates [173–175]. These substances are both a substrate and
an inhibitor for CYP2D6 [176]. As CYP3A4 and CYP2D6 cytochromes are able to metabolize most drugs,
the inhibition of these enzymes, could become a significant problem [135]. Bedada et al. [177] conducted
a comparative study for the evaluation of khat effects on the enzymatic activity of cytochrome P450
(CYP) 2D6 and CYP3A4. The test was conducted on 40 ethiopian volunteers. Dextromethorphane and
khat were administered, the first as a probe drug. Genotyping of the CYP2D6*3 and CYP2D6*4 were
performed. In conclusion, inhibition of CYP2D6 activity by khat was more important in CYP2D6*1/*1
compared to CYP2D6*1/*4 genotypes. A marginal inhibition of CYP3A4 activity was observed in the
presence of khat [177].
3. Materials and Methods
The identification of relevant scientific articles was performed via the following research
engines: Medline, Cochrane Central, Scopus, Web of Science, Science Direct, EMBASE and Google
Scholar, up to December 2015 using the following keywords for Kava: “Kava”, “Piper methysticum”
“Hepatotoxicity”, “Liver” “Injury”, “Toxicity”. The main keywords “Kava” and “Piper methysticum”
were individually searched and then again in association to each of the others. The 738 and
773 sources initially found, with “Kava” and “Piper methysticum”, respectively, were selected in
order to exclude papers not appropriate for the purpose of the review and duplicate sources. Only
74 papers [8,11,12,15,16,26–28,70–76,103–161] (40 research articles, 15 review articles, 2 randomized
controlled trials, 9 case report/series, 5 letters to the editor, 1 report, 1 book chapter and 1 meta-analysis)
were included in the results.
The following keywords were used for Kratom: “Kratom”, “Mitragyna speciosa”, “Mitragynine
alkaloids”, “toxicity” and “hepatotoxicity”. The main keywords “Kratom” and “Mitragyna speciosa”
were individually searched and then again in association to each of the others. The 71 and 115 sources
originally found, with “Kratom” and “Mitragyna speciosa”, respectively, were selected in order to
exclude papers not suitable for the aim of the review or duplicate sources.
Only 33 papers [32,37,41,42,45,49,52–54,77–86,89–95,162–168] (5 review articles, 1 letter to editor,
7 case reports, 16 research articles, 1 short communication, 1 Ph.D. thesis, 2 book chapters) were
included in the results.
The following keywords were used for Khat: “Khat”, “Catha edulis”, “Hepatotoxicity”, “Liver”
“Injury”, “Toxicity”. The main keywords “Khat” and “Catha edulis” were individually searched and
then again in association to each of the others. The 583 and 536 sources primarily found, with “Khat”
and “Catha edulis”, respectively, were initially identified in order to exclude papers not appropriate
for the purpose of this review and duplicate sources. Only 21 papers [59,64–66,96–102,135,169–177]
(13 research articles, 5 reviews, 3 case reports) were included in the results.
All sources have been screened by three of the authors independently, and in order to be included
they had to be selected by at least two of the authors.
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4. Conclusions
Despite the fact that several experimental studies have already been published in order to
show kava mechanisms of hepatotoxicity, including direct toxicity performed by kava constituents,
GSH depletion, COX inhibition, reactive metabolites, the interference with CYP-450 enzymes,
carcinogenesis studies and the intervention of contaminants, mold hepatotoxins, extraction procedures
and inflammation, the mechanisms of kava hepatotoxicity are still not fully elucidated in humans.
Moreover, according to the examination of kava toxicity in reports performed by different authors,
the occurrence of liver toxicity due to kava products seems to be extremely rare. Its manifestation is
suggested to be in relationship with a lack of compliance to recommended dose/overdosing or with a
co-ingestion of herbal supplements or other substances or as a consequence of non-standardization of
the kava products [178]. Furthermore, the ban imposed in Germany on the herbal supplement kava
was overturned in 2014, after the decisions of two administrative German Courts [179–181].
Literature reports about mitragynine toxicity in humans are rare, even if in recent years clinical
cases are increasing. Only two papers [52,93] reported cases of hepatotoxicity following kratom
consumption; the first one was published by Kapp et al. [54] in 2011 involving a 25-year-old man, the
second one was described by Dorman et al. [95] in 2015, involving a 58 year old man.
Although in both cases the available data were significantly suggestive of kratom induced
hepatotoxicity, the authors of both studies due to the lack of scientific data on the toxicity of kratom in
humans, were cautious in confirming unequivocally this association; in the first case [52] the physicians
could not directly correlate the onset of acute liver disease with the intake of kratom, taking into account
that the effects of the substances contained in M. speciosa extract (alkaloids, saponins, flavonoids, etc.)
have not yet been fully investigated making the correlation between the state of the liver and the
intake of these preparations very difficult, whereas in the second case report [93], the authors defined
idiosyncratic the onset of liver complications but evaluated as “convincing” its association with the
intake of kratom. However, it still remains to be established if the onset of liver complications could be
attributable to kratom alkaloids, extract-production byproducts, or other contaminants [52].
In the literature, there are an increasing number of cases of severe liver injury as a consequence of
khat use or abuse, in particular in the UK, Holland and other European countries where Catha edulis is
legal [62–64,169]. In many cases, a common factor is the occurrence of non-viral hepatitis with khat uses.
Up to this moment, the enzymes included in metabolism of khat have not yet been fully described,
however it is supposed that P450 (CYP) is involved because many recent studies have identified
CYP2D6 as the enzyme included in the metabolism of synthetic cathinone derivates [173–175].
This review allow us to conclude that if, on the one hand, some of the mechanisms underlying
kava hepatotoxicity have been identified, several other aspects still need clarification, while, on the
other hand, kratom and khat hepatotoxicity must still be elucidated and only through a careful
evaluation of each case together with further experimental studies will it be possible to increase the
knowledge in this field.
5. Limitations of the Review
A limitation of this review is related to the fact that, although in the literature, the assessment of
causality for hepatotoxicity due to kava was carried out through the use of valid assessment methods
such as the RUCAM, this evaluation has not been applied systematically in suspected cases of kratom
and khat related hepatotoxicity.
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